Literature DB >> 22914896

Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients.

David Eric Ouedraogo1, Alain Makinson, Nils Kuster, Nicolas Nagot, Pierre-Alain Rubbo, Karine Bollore, Vincent Foulongne, Guillaume Cartron, Daniel Olive, Jacques Reynes, Jean-Pierre Vendrell, Edouard Tuaillon.   

Abstract

BACKGROUND: Despite the use of combined antiretroviral therapy, HIV-infected individuals have a higher risk of developing B-cell lymphoma compared to the general population. We aim to explore whether lymphocyte activation, increase in Th1 response as well as markers of EBV reactivation, may precede lymphoma diagnosis.
METHODS: Thirteen cases and 26 controls matched on CD4(+) T-cell count and HIV plasma viral load were identified. Samples were collected 0 to 5 years prior to B-cell lymphoma diagnosis. Seven out of 13 (54 %) and 16/26 (61.5 %) of cases and controls were receiving antiretroviral therapy at the time of sampling, respectively. CD8(+) T-cell activation and Th1 cytokine concentrations were measured before lymphoma onset, together with IgG antibodies directed against viral capsid antigen (VCA) and serum levels of EBV DNA.
RESULTS: A higher level of CD8(+) T-cell activation was observed in patients developing lymphoma. Four out of seven Th1 cytokine serum concentrations were significantly higher in patients with lymphoma than in the control group: IL-2R, IL-12p40/70, IFN-γ-inducible protein 10 (IP-10) and monokine induced by IFN-γ (MIG). Anti-VCA IgG level were significantly higher in cases than in controls. Four cases (30 %) but no controls had detectable EBV DNA in serum.
CONCLUSION: A higher level of T-cell activation, Th1 cytokine serum concentration and markers of EBV replication, preceded B-cell lymphoma diagnosis. This may suggest that viral antigen stimulation is associated with the genesis of lymphoma in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914896     DOI: 10.1007/s10875-012-9766-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  61 in total

1.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

2.  Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma.

Authors:  Olivier Gasser; Marcel Wolbers; Ingrid Steffen; Hans H Hirsch; Manuel Battegay; Christoph Hess
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

3.  CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7.

Authors:  Marta Catalfamo; Christopher Wilhelm; Lueng Tcheung; Michael Proschan; Travis Friesen; Jung-Hyun Park; Joseph Adelsberger; Michael Baseler; Frank Maldarelli; Richard Davey; Gregg Roby; Catherine Rehm; Clifford Lane
Journal:  J Immunol       Date:  2011-01-21       Impact factor: 5.422

4.  High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology.

Authors:  Servi J C Stevens; Brian S N Blank; Paul H M Smits; Pieter L Meenhorst; Jaap M Middeldorp
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

5.  Trends in cancer risk among people with AIDS in the United States 1980-2002.

Authors:  Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

6.  Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.

Authors:  Edouard Tuaillon; Yassine Al Tabaa; Vincent Baillat; Michel Segondy; Marie-Christine Picot; Jacques Reynes; Jean-Pierre Vendrell
Journal:  Cytometry B Clin Cytom       Date:  2009-07       Impact factor: 3.058

7.  CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.

Authors:  Z Liu; W G Cumberland; L E Hultin; A H Kaplan; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-08-01

8.  Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.

Authors:  Servi J C Stevens; Paul H M Smits; Sandra A W M Verkuijlen; Davy A P Rockx; Eric C M van Gorp; Jan W Mulder; Jaap M Middeldorp
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

9.  The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value.

Authors:  M Levacher; F Hulstaert; S Tallet; S Ullery; J J Pocidalo; B A Bach
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

10.  A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.

Authors:  Anupa Kamat; Vikas Misra; Edana Cassol; Petronela Ancuta; Zhenyu Yan; Cheng Li; Susan Morgello; Dana Gabuzda
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  6 in total

1.  Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Marta Epeldegui; Otoniel Martínez-Maza
Journal:  For Immunopathol Dis Therap       Date:  2015

2.  CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy.

Authors:  Yonggui Tian; Chunli Wen; Zhen Zhang; Yanfen Liu; Feng Li; Qitai Zhao; Chang Yao; Kaiyuan Ni; Shengli Yang; Yi Zhang
Journal:  Cancer Immunol Immunother       Date:  2022-03-29       Impact factor: 6.630

3.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

4.  Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.

Authors:  Elena Vendrame; Shehnaz K Hussain; Elizabeth Crabb Breen; Larry I Magpantay; Daniel P Widney; Lisa P Jacobson; Daina Variakojis; Emilee R Knowlton; Jay H Bream; Richard F Ambinder; Roger Detels; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

5.  Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma.

Authors:  Brian M Nolen; Elizabeth Crabb Breen; Jay H Bream; Frank J Jenkins; Lawrence A Kingsley; Charles R Rinaldo; Anna E Lokshin
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

6.  Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.

Authors:  Marta Epeldegui; David V Conti; Yu Guo; Wendy Cozen; Manuel L Penichet; Otoniel Martínez-Maza
Journal:  Sci Rep       Date:  2019-06-28       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.